#1 Clinical Trials Search in Europe

Ifezuntirgene Inilparvovec

This article discusses the ongoing clinical trials of Ifezuntirgene Inilparvovec, also known as AMT-130, for the treatment of early Huntington’s Disease. AMT-130 is an innovative gene therapy designed to lower the expression of the toxic huntingtin protein in affected areas of the brain. The trials aim to evaluate the safety, tolerability, and potential efficacy of this groundbreaking treatment approach for individuals with early manifest Huntington’s Disease.

Table of Contents

What is IFEZUNTIRGENE INILPARVOVEC?

IFEZUNTIRGENE INILPARVOVEC, also known as AMT-130 or AAV5-miHTT, is an innovative gene therapy being developed to treat Huntington’s disease (HD). Huntington’s disease is a rare, inherited disorder that causes progressive brain damage, affecting movement, thinking, and emotions[1].

How Does It Work?

This therapy uses a specially engineered virus called adeno-associated virus serotype 5 (AAV5) to deliver genetic material to specific areas of the brain. The genetic material contains instructions for producing micro RNA (miRNA) that targets the huntingtin (HTT) gene. By targeting this gene, the therapy aims to reduce the production of the toxic huntingtin protein responsible for the symptoms of Huntington’s disease[1].

The treatment works through a natural process called RNA interference (RNAi). By lowering the levels of toxic mutant HTT mRNA and protein in the brain regions affected by HD, researchers hope to slow down or potentially halt the progression of the disease[1].

Clinical Trial Details

A clinical trial is currently underway to evaluate the safety and potential effectiveness of IFEZUNTIRGENE INILPARVOVEC. This trial is a Phase Ib/II study, which means it’s testing both the safety and early signs of effectiveness in patients with early manifest Huntington’s disease[1].

The study includes three groups (cohorts) of participants:

  • Cohort 1: Receives a low dose of AMT-130
  • Cohort 2: Receives a high dose of AMT-130
  • Cohort 3: Participants are randomly assigned to receive either the low or high dose

The therapy is administered directly into the brain through a surgical procedure called intracerebral delivery. Participants will be followed for 5 years after receiving the treatment to assess its long-term effects and safety[1].

Potential Benefits

The goal of this therapy is to potentially slow down or stop the progression of Huntington’s disease. Researchers hope that by reducing the levels of toxic huntingtin protein in the brain, they can preserve brain function and improve the quality of life for people with HD[1].

Safety Considerations

As with any experimental treatment, there are potential risks involved. The clinical trial is designed to carefully monitor participants for any side effects or safety concerns. Some of the key safety measures include:

  • Regular check-ups and medical tests
  • Brain scans to monitor for any changes
  • Blood and spinal fluid tests
  • Assessments of thinking abilities and mental health

It’s important to note that this therapy involves a surgical procedure to deliver the treatment directly to the brain, which carries its own risks[1].

Eligibility Criteria

The clinical trial has specific criteria for who can participate. Some key eligibility requirements include:

  • Adults aged 25 to 65 years
  • Diagnosed with early manifest Huntington’s disease
  • Genetic confirmation of HD (40 or more CAG repeats in the huntingtin gene)
  • Specific brain volume requirements
  • No other significant medical conditions that could interfere with the study

There are also several exclusion criteria, such as recent suicide attempts, certain medical procedures, or participation in other experimental treatments[1].

Conclusion

IFEZUNTIRGENE INILPARVOVEC represents a promising approach to treating Huntington’s disease. By targeting the root cause of the disease at the genetic level, this therapy offers hope for potentially slowing or stopping the progression of HD. However, it’s important to remember that this treatment is still in the experimental stage, and more research is needed to fully understand its effectiveness and safety[1].

Aspect Details
Drug Name Ifezuntirgene Inilparvovec (AMT-130)
Trial Phase Phase Ib/II
Condition Early manifest Huntington’s Disease
Mechanism Gene therapy targeting huntingtin (HTT) gene
Administration One-time intra-striatal injection
Cohorts 3 cohorts (low dose, high dose, and expansion)
Follow-up Duration 5 years post-treatment
Primary Endpoints Safety, tolerability, and various clinical measures
Key Eligibility Adults 25-65 years, ≥40 CAG repeats, specific disease progression criteria

FAQ

  • What is Ifezuntirgene Inilparvovec (AMT-130)? Ifezuntirgene Inilparvovec, or AMT-130, is a gene therapy designed to treat Huntington's Disease. It uses a virus (AAV5) to deliver genetic material that produces micro RNA targeting the huntingtin gene. This aims to reduce the production of the toxic huntingtin protein in the brain, which is believed to be responsible for the symptoms of Huntington's Disease.
  • How is AMT-130 administered in the clinical trials? AMT-130 is administered through a one-time intra-striatal injection directly into the brain. The procedure involves a neurosurgical operation that lasts approximately 10 hours. Different doses are being tested in the trials to determine the most effective and safe amount.
  • Who is eligible to participate in these clinical trials? The trials are open to adults aged 25 to 65 with early manifest Huntington's Disease. Participants must have a confirmed genetic diagnosis with 40 or more CAG repeats in the huntingtin gene, and meet specific criteria regarding disease progression and brain structure. There are also various health-related inclusion and exclusion criteria to ensure participant safety.
  • What are the main objectives of these clinical trials? The primary objectives are to evaluate the safety and tolerability of AMT-130 in patients with early Huntington's Disease. Secondary objectives include assessing how long AMT-130 persists in the brain and monitoring various markers of disease progression and treatment effect.
  • How long will participants be followed in these trials? Participants who receive AMT-130 will be followed for a total of 5 years after the treatment. This includes a 12-month post-treatment follow-up period and a 4-year long-term follow-up period to monitor safety, efficacy, and long-term effects of the therapy.

Ongoing Clinical Trials on Ifezuntirgene Inilparvovec

  • Study on the Safety and Effects of AMT-130 for Adults with Early Huntington’s Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • Huntington's Disease (HD): A genetic disorder that causes progressive brain damage, affecting movement, thinking, and emotions. It's caused by a faulty gene that produces a toxic protein called huntingtin.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, AMT-130 is designed to reduce the production of the harmful huntingtin protein.
  • CAG repeats: A section of DNA in the huntingtin gene that is repeated multiple times. In Huntington's Disease, there are 40 or more of these repeats, which leads to the production of the toxic huntingtin protein.
  • Intra-striatal injection: A method of delivering medication directly into the striatum, a part of the brain affected in Huntington's Disease.
  • AAV5: Adeno-Associated Virus serotype 5, a type of virus used in gene therapy to deliver genetic material into cells. It's modified to be safe and non-disease causing.
  • Micro RNA (miRNA): Small molecules that can regulate gene expression. In this therapy, miRNA is used to reduce the production of the huntingtin protein.
  • UHDRS TFC score: Unified Huntington's Disease Rating Scale Total Functional Capacity score, a measure used to assess the functional abilities of individuals with Huntington's Disease.
  • Manifest Huntington's Disease: The stage of Huntington's Disease where symptoms are clearly present and affecting daily life.
  • Striatum: A part of the brain that plays a crucial role in movement control and is particularly affected in Huntington's Disease.
  • RNA interference (RNAi): A biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-amt-130-for-adults-with-early-huntingtons-disease/